Search

Displaying results 8511 - 8520 of 10000 in total
  1. Drug

    Alcuronium

    go.drugbank.com/drugs/DB13648
    Experimental

    A non-depolarizing skeletal muscle relaxant similar to [tubocurarine]. It is used as an anesthesia adjuvant.

  2. Drug

    Propionate ion

    go.drugbank.com/drugs/DB19384
    Investigational

    Propionate ion is under investigation in clinical trial NCT00846326 (Preventing Tolerance to Oxymetazoline in Allergic Rhinitis).

  3. Drug

    Gusperimus

    go.drugbank.com/drugs/DB12692
    Investigational

    Gusperimus has been used in trials studying the treatment of Lupus Nephritis, Wegeners Granulomatosis, and Wegener's Granulomatosis.

  4. Drug

    Racecadotril

    go.drugbank.com/drugs/DB11696
    Investigational

    Racecadotril has been investigated for the basic science and treatment of Diarrhea, Acute Diarrhea, and Acute Gastroenteritis.

  5. Drug

    MEDI-491

    go.drugbank.com/drugs/DB17859
    Experimental

    MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.

  6. Drug

    CEB-01

    go.drugbank.com/drugs/DB18505
    Investigational

    CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin

  7. Drug

    PARPI F-18

    go.drugbank.com/drugs/DB18657
    Experimental

    PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.

  8. Drug

    Canvuparatide

    go.drugbank.com/drugs/DB18658
    Investigational

    Canvuparatide is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.[L48365]

  9. Drug

    Aminoflavone

    go.drugbank.com/drugs/DB19077
    Investigational

    Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).

  10. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.